On Wednesday, Msci Inc (NYSE:MSCI)’s shares inclined 0.72% to $61.41.
MSCI Inc. (MSCI), a leading provider of research-based indexes and analytics, reports a surge in demand for Environmental, Social and Governance (ESG) data and indexes.
As of July 2015, equity ETF assets tracking MSCI ESG Indexes grew nearly 30% to $1.8 billion during 2015. Since December 2013, assets have more than doubled, rising by 140%, with 22 new ESG ETFs tracking MSCI indexes. So far in 2015, ten of the 11 ESG ETF’s launched have been based on MSCI indexes, accounting for 96% of the total flows in the category.
ETFs tracking the MSCI Low Carbon Indexes accounted for nearly 80% of the total equity ETF assets of carbon themed ETFs since their launch in September 2014, bringing low carbon ETF assets to more than $460 million as of July 2015.
MSCI Inc., together with its auxiliaries, provides investment decision support tools worldwide. Its tools comprise indexes, portfolio risk and performance analytics, and multi-asset class market risk analytics products and services.
Affymetrix, Inc. (NASDAQ:AFFX)’s shares gained 1.24% to $9.01.
Affymetrix, Inc. (AFFX) declared that it has been selected as the genotyping supplier by the Green Super Rice project coordinated by the Chinese Academy of Agricultural Sciences as part of their effort to develop, within the next three years, at least fifteen new rice varieties and deliver them to small-hold farmers in 16 countries in Africa and Asia, counting China.
The Green Super Rice (GSR) project comprises building a highly efficient genotyping platform for the large-scale molecular breeding activities within the international rice research community. The Green Super Rice project is supported by the Chinese government and the Bill & Melinda Gates Foundation, and aims to enhance the income of resource-limited rice producers by the development and wide-adoption of GSR varieties and corresponding crop administration technology. The long-term aim of the project is to benefit at least 20 million resource-limited rice farmers and to boost rice productivity by 20% in the target countries.
Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia. The company operates in two segments, Affymetrix Core and eBioscience. The Affymetrix Core segment engages in the development, manufacture, and commercialization of systems for genetic analysis in the life sciences and diagnostic industry.
At the end of Wednesday’s trade, Chimera Investment Corporation (NYSE:CIM)‘s shares surged 0.63% to $14.47.
The Board of Directors of Chimera declared the declaration of its third quarter 2015 cash dividend of $0.48 per common share. This dividend is payable October 30, 2015, to common stockholders of record on September 30, 2015. The ex-dividend date is September 28, 2015.
The Board of Directors also declared that it anticipates maintaining a minimum quarterly dividend of $0.48 for the fourth quarter of 2015.
Chimera Investment Corporation operates as a real estate investment trust in the United States. The company, through its auxiliaries, invests in residential mortgage-backed securities (RMBS), residential mortgage loans, commercial mortgage loans, real estate-related securities, and various other asset classes.
Unilife Corp (NASDAQ:UNIS), ended its Wednesday’s trading session with -8.56% loss, and closed at $0.960.
Unilife Corporation (UNIS), a developer and supplier of injectable drug delivery systems, recently declared its financial results for the fiscal fourth quarter and full fiscal year ending June 30, 2015.
Following the development of the Imperium™ platform of insulin patch pumps declared last month, Unilife has now established a full portfolio of products and capabilities to serve customers across all target market segments. By concluding the development stage of its strategy, the Company can now focus its resources entirely on the customization and commercialization of existing products under current and prospective customer supply agreements. Under a cost reduction and business realignment initiative implemented recently, the Company has reduced its workforce by about 50 employees, or about 17% of its workforce, and the Company will significantly reduce its operating expenses in fiscal 2016.
Contrast to the annualized run rate for operating expenses in the fourth quarter of fiscal year 2015, R&D expense in fiscal 2016 is anticipated to decrease by 25% to 30% and SG&A expense by about 20%. These comparisons exclude share-based compensation and depreciation expense. As a result of this initiative, we expect to record a charge of about $0.4 million for severance and related costs in the first fiscal quarter of 2016.
Unilife Corporation designs, manufactures, and supplies injectable drug delivery systems in the United States and internationally. The company offers Unifill, a pre-filled syringe with integrated, automatic, and user-controlled retraction; Unifill Finesse, an integrated, automatic, and user-controlled retraction with standard plunger seal and plunger rod; Unifill Select, which allows an end-user to select and attach a needle at the time of injection; Unifill Nexus that is equipped with an integrated luer adapter to provide connectivity with needleless luer access devices; and Unifill Allure, that allows the end-user to select and attach a needle with a universal luer connection at the time of injection with automatic, user-controlled needle retraction.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
